bpc 157 clinicaltrials gov nct Frontiers tm267368d1_6kimg023.jpg

The report highlights early metabolic studies, selected clinical trials, and certain double-blind placebo-controlled investigations that examined markers such as: blood sugar regulation insulin sensitivity cholesterol levels impaired glucose tolerance adipose tissue activity fat release and lipolytic activity While these studies generated interest in AOD-9604 as a potential anti-obesity drug candidate , the report stresses that no authority recognizes it as an active treatment for obesity, weight loss, or human use and emphasizes that it remains designated strictly for research use

For adults under 60 with normal absorption, both work well

My aim is to protect the integrity of peptide research by ensuring fake and counterfeit bottles stay off the market.

All of them share the same caveats: prescription level, supervision required, and off limits for tested competition